Lyvispah is owned by Amneal.
Lyvispah contains Baclofen.
Lyvispah has a total of 2 drug patents out of which 0 drug patents have expired.
Lyvispah was authorised for market use on 22 November, 2021.
Lyvispah is available in granules;oral dosage forms.
Lyvispah can be used as treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity; treatment of spasticity resulting from spinal cord injuries and other spinal cord diseases, method for treating spasticity.
The generics of Lyvispah are possible to be released after 29 September, 2041.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US10792262||AMNEAL||Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives|| |
(16 years from now)
|US11491125||AMNEAL||Baclofen formulations and methods of minimizing patient exposure to metabolite variations|| |
(18 years from now)
Drugs and Companies using BACLOFEN ingredient
Market Authorisation Date: 22 November, 2021
Treatment: Method for treating spasticity; Treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity; Treatment o...
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic